Venous thromboembolism (VTE) remains a leading preventable cause of death in hospitalized patients and accounts for approximately 100,000 to 300,000 deaths per year in the United States alone. Acutely ill medical patients are an especially vulnerable group within a hospital setting. They are at risk for what is known as “double trouble:”
Current international guidelines, including those of the American College of Chest Physicians (ACCP), recommend an individualized risk assessment strategy to determine a hospitalized patient’s risk of both VTE and bleeding to guide VTE prevention. Numerous clinical VTE risk assessment models focusing on the medically ill have recently been reported in the literature.
In this webinar, Dr. Spyropoulos will discuss recent advances in both the use of clinical VTE risk assessment models and potential VTE biomarkers to identify patients at higher risk for VTE and to improve prevention of VTE among hospitalized patients. He will also discuss potential future utility of these strategies to identify particularly high-risk patients who would benefit from extended (long-term) thromboprophylaxis to prevent VTE.